D. Boral Capital Reiterates “Buy” Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)‘s stock had its “buy” rating reiterated by investment analysts at D. Boral Capital in a research note issued on Monday,Benzinga reports. They currently have a $2.00 price objective on the stock. D. Boral Capital’s price objective suggests a potential upside of 17.65% from the stock’s current price.

Separately, HC Wainwright reiterated a “buy” rating and set a $9.00 price objective on shares of Lineage Cell Therapeutics in a research report on Monday, November 24th. Three research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $4.67.

Lineage Cell Therapeutics Stock Performance

NYSEAMERICAN:LCTX opened at $1.70 on Monday. The stock has a market cap of $391.56 million, a price-to-earnings ratio of -5.86 and a beta of 1.80. Lineage Cell Therapeutics has a 1 year low of $0.37 and a 1 year high of $2.09. The business has a fifty day moving average of $1.68 and a 200-day moving average of $1.55.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.13) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.02) by ($0.11). The company had revenue of $3.68 million during the quarter, compared to analyst estimates of $2.30 million. Lineage Cell Therapeutics had a negative return on equity of 72.02% and a negative net margin of 625.53%. On average, equities research analysts predict that Lineage Cell Therapeutics will post -0.12 EPS for the current year.

Institutional Trading of Lineage Cell Therapeutics

Hedge funds have recently modified their holdings of the company. Royal Bank of Canada grew its position in shares of Lineage Cell Therapeutics by 1,578.9% in the 1st quarter. Royal Bank of Canada now owns 528,656 shares of the company’s stock valued at $237,000 after purchasing an additional 497,168 shares during the period. Rhumbline Advisers lifted its stake in Lineage Cell Therapeutics by 9.9% in the first quarter. Rhumbline Advisers now owns 201,447 shares of the company’s stock valued at $91,000 after buying an additional 18,092 shares in the last quarter. Defender Capital LLC. lifted its stake in Lineage Cell Therapeutics by 7.5% in the second quarter. Defender Capital LLC. now owns 6,785,177 shares of the company’s stock valued at $6,157,000 after buying an additional 474,304 shares in the last quarter. Cannon Global Investment Management LLC acquired a new position in shares of Lineage Cell Therapeutics in the second quarter valued at approximately $30,000. Finally, Ground Swell Capital LLC bought a new stake in shares of Lineage Cell Therapeutics during the second quarter worth $95,000. 62.47% of the stock is currently owned by institutional investors and hedge funds.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel, allogeneic cell therapies built on pluripotent stem cell platforms. The company focuses on three primary therapeutic areas—retinal disease, neural repair and immune-effector cell oncology—leveraging its proprietary manufacturing processes to create off-the-shelf cell therapy candidates designed for broad patient populations.

Its lead candidate, OpRegen, comprises retinal pigment epithelium cells intended to slow or reverse vision loss in patients with geographic atrophy secondary to age-related macular degeneration.